CONSHOHOCKEN, Pa. / ATLANTA, Ga., March 23, 2026 — U.S. drug distributor Cencora said Monday it will buy the retina-care business of EyeSouth Partners in a deal valued at $1.1 billion, a move that expands its presence in specialty medical services and reflects continued consolidation in healthcare distribution and care delivery. The agreement will integrate retina-focused physicians from the privately held EyeSouth network into Cencora’s existing eye-care operations, building on the Retina Consultants of America platform that Cencora acquired in 2024 for approximately $4.6 billion.
Shares of Cencora rose more than two percent in premarket trading as investors reacted positively to the expansion of its specialty services portfolio. Over the past year, the company has sold non-core units while acquiring physician networks that deliver high-value therapies, signaling a deliberate shift toward service-oriented growth.
Deal Structure and Strategic Direction
Integration with Retina Consultants of America: EyeSouth Partners’ retina practices will join Cencora’s Retina Consultants of America platform, uniting two retina-focused provider networks under a single operational framework. This integration allows the company to align administrative and clinical functions across a larger set of physicians while maintaining continuity of patient care. Shared clinical insights, coordinated treatment schedules, and patient access initiatives are expected to benefit from this consolidation.
Alignment with Specialty Services Expansion: The acquisition reflects Cencora’s strategy of growing into specialty medical services where physician-administered therapies play a central role. Retina-focused practices provide treatments that require frequent administration and careful handling, creating opportunities to integrate distribution with clinical coordination. By expanding into this segment, Cencora strengthens its presence in higher-value therapies and extends its reach in ophthalmology beyond traditional pharmaceutical distribution.
Retina Care in Focus
Retinal diseases such as age-related macular degeneration and diabetic retinopathy require complex treatment plans and ongoing monitoring. Specialists often administer high-cost therapies in clinical settings, which calls for precise coordination of timing, storage, and delivery. Companies like Cencora can support these processes by offering integrated services that connect distribution with patient care.
The addition of EyeSouth’s retina business comes as the ophthalmology drug market evolves with new biosimilar therapies. These treatments are expected to broaden patient access and drive demand, creating opportunities for distributors that manage physician-administered therapies efficiently. Integration into the RCA platform allows Cencora to unify operational functions, support clinical research, and expand patient services across a wider network of providers.
Broader Mergers and Acquisitions Context
Cencora’s acquisition illustrates a broader trend of healthcare distributors expanding into specialty segments where patient care and distribution intersect. Large companies have been adding networks focused on ophthalmology, oncology, and other physician-administered arenas to diversify revenue streams. Competitors such as McKesson have pursued similar strategies, acquiring retina-focused practices to strengthen service capabilities and regional reach.
The deal highlights the value of established provider networks. Practices with recurring patient engagement and treatment volumes command strong valuations, reflecting their role in delivering ongoing care. Transactions like this demonstrate how companies are reallocating resources toward higher-value specialties while divesting non-core operations.
Financial and Market Considerations
The $1.1 billion valuation underscores the market’s recognition of retina practices as strategic assets. These practices generate consistent demand through frequent patient visits and high-cost therapies. The transaction is structured to contribute to Cencora’s adjusted earnings per share within 12 months of closing, after accounting for financing costs, and remains subject to customary closing conditions, including regulatory approvals.
Cencora has not included benefits from the EyeSouth transaction in its current annual financial outlook, reflecting that the deal may not close within the current fiscal period. The company’s acquisitions continue to reshape its portfolio, positioning it to participate in segments where treatment delivery, patient care, and distribution converge.
Future Outlook
Once completed, the integration of EyeSouth’s retina business will further consolidate Cencora’s position in specialty medical services. By combining distribution with physician-administered care, the company gains a stronger platform to support clinical operations, patient access, and research initiatives. The deal also signals how healthcare companies are redefining their roles in markets where chronic and specialty treatments demand coordinated, ongoing care.
Cencora’s expansion into retina services reflects both a strategic focus on high-value therapies and a broader trend in healthcare consolidation, where service integration and patient outcomes are driving business decisions. With an aging population and growing prevalence of retinal diseases, the acquisition positions Cencora to meet rising demand while reinforcing its presence in a critical segment of ophthalmology.
Cencora’s acquisition illustrates a broader trend of healthcare distributors expanding into specialty segments where patient care and distribution intersect. Large companies have been adding networks focused on ophthalmology, oncology, and other physician-administered arenas to diversify revenue streams.
